US › Healthcare

Bolt Biotherapeutics (BOLT)

US · Healthcare · Biotechnology

$3.95-0.75%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$26,000
Revenue YoY
-97.9%
Net profit
$-7.2M
Profit YoY
+34.4%
EPS
$-4.31
EPS estimate
$-3.60
Net margin
-27,861.5%

EPS came in at -4.31 against a street estimate of -3.60 — a miss of 19.7%.

Key statistics

Market cap
$7.7M
Forward P/E
0.0
P/B
0.39
Book value
$10.32
EPS (TTM)
$-16.40
52-week high
$7.20
52-week low
$3.75
50-day MA
$4.34
200-day MA
$4.95
Beta
1.17

Analyst view

Analysts rate Bolt Biotherapeutics a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $41.00.

Shareholding

Insiders
3.47%
Institutions
28.87%

Largest institutional holders

FundStake
Sofinnova Ventures7.17%
Renaissance Technologies Corp4.02%
Vivo Capital, LLC3.77%
Pivotal bioVenture Partners Investment Advisor LLC2.22%
T3 Companies, LLC1.98%
Board of Ttees Leland Stanford Jr Univ1.87%
Pfizer Inc1.63%
Lynx1 Capital Management, LP1.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bolt Biotherapeutics — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.